{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cancer+Pancreas&page=2", "query": { "condition": "Metastatic Cancer Pancreas", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cancer+Pancreas&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T08:32:05.460Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03207867", "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC, Non Small Cell Lung Cancer", "RCC, Renal Cell Cancer", "Pancreatic Cancer", "Urothelial Cancer", "Head and Neck Cancer", "DLBCL, Diffused Large B Cell Lymphoma", "MSS, Microsatellite Stable Colon Cancer", "TNBC, Triple Negative Breast Cancer", "Melanoma", "mCRPC, Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "NIR178", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 315, "start_date": "2017-08-28", "completion_date": "2023-02-14", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-07-24T08:32:05.460Z", "location_count": 5, "location_summary": "Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03207867" }, { "nct_id": "NCT01660971", "title": "Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IV Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2012-07-30", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-07-24T08:32:05.460Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01660971" }, { "nct_id": "NCT01830322", "title": "Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "CPI-613", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Any non-gemcitabine chemotherapies or best supportive care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cornerstone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 0, "start_date": "2014-01", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2013-08-14", "last_synced_at": "2026-07-24T08:32:05.460Z", "location_count": 2, "location_summary": "The Bronx, New York • Temple, Texas", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01830322" }, { "nct_id": "NCT03126435", "title": "EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Pancreas Cancer", "Locally Advanced Pancreatic Cancer", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "EndoTAG-1", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SynCore Biotechnology Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 218, "start_date": "2018-10-16", "completion_date": "2021-10-08", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-07-24T08:32:05.460Z", "location_count": 16, "location_summary": "Corona, California • Atlanta, Georgia • Columbus, Georgia + 12 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126435" }, { "nct_id": "NCT00593008", "title": "Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2007-10", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2011-12-02", "last_synced_at": "2026-07-24T08:32:05.460Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00593008" }, { "nct_id": "NCT06005493", "title": "Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastro-esophageal Junction Cancer", "Pancreatic Ductal Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "AZD5863", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2023-07-11", "completion_date": "2027-07-16", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-07-24T08:32:05.460Z", "location_count": 3, "location_summary": "Jacksonville, Florida • Rochester, Minnesota • New York, New York", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06005493" }, { "nct_id": "NCT06974734", "title": "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non Small Cell Lung", "Carcinoma, Pancreatic Ductal", "Malignant Melanoma", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "PF-08046037", "type": "DRUG" }, { "name": "sasanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2025-05-06", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-07-24T08:32:05.460Z", "location_count": 14, "location_summary": "Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974734" }, { "nct_id": "NCT03323944", "title": "CAR T Cell Immunotherapy for Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Cancer of the Pancreas" ], "interventions": [ { "name": "huCART-meso cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2017-09-15", "completion_date": "2025-02-20", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-07-24T08:32:05.460Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03323944" }, { "nct_id": "NCT06179160", "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB161734", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "GEMNabP", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "INCA33890", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 710, "start_date": "2024-01-04", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-24T08:32:05.460Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179160" }, { "nct_id": "NCT03146962", "title": "High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Pancreatic Cancer", "Lung Cancer" ], "interventions": [ { "name": "Vitamin C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2017-03-29", "completion_date": "2023-04-21", "has_results": true, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-07-24T08:32:05.460Z", "location_count": 2, "location_summary": "Brooklyn, New York • New York, New York", "locations": [ { "city": "Brooklyn", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03146962" } ] }